The PKMYT1 kinase has emerged as a promising therapeutic target for CCNE1-amplified cancers, after a recently reported genome-scale CRISPR/Cas9-based screen identified its inhibition as synthetically lethal for CCNE1 amplification.
Merck KGaA provided details on the discovery of MSC-4106, an orally active lead compound binding to the lipidation pocket (P-site) of the TEAD1 transcription factor and capable of disrupting its interaction with the transcriptional cofactors YAP and TEAZ, thereby preventing the formation of the YAP/TAZ-TEAD transcriptional complex.
“The association between air pollution and lung cancer is not new,” Charles Swanton told the audience at the European Society of Medical Oncology (ESMO) 2022 Congress. But as with so many associations, causation has been hard to establish, partly due to the puzzling absence of mutations.
BioWorld Science has now been migrated onto the same platform as the full suite of BioWorld news services, providing an improved experience and expanded news offering.
The new site features many enhancements, which you can read about here. Frequently Asked Questions are answered here.
In addition to BioWorld Science content, you can now read headlines and summaries from the flagship news service, BioWorld, as well as BioWorld MedTech and BioWorld Asia. You’ll also find access to special reports and the BioWorld Insider podcast.
We're excited to offer an upgraded experience and thank you for reading.
Autobahn Therapeutics Inc. has closed a US$32.7 million financing to support the company's continued work in the treatment of central nervous system (CNS) disorders and the advancement of ABX-002 through phase I and into phase II proof-of-concept studies for treatment-resistant depression (TRD).
Quince Therapeutics Inc. (formerly Novosteo Inc.) has presented data on NOV-004, a construct that delivers abaloparatide therapeutic agent into the fracture site, designed for the treatment of osteogenesis imperfecta.
Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented preclinical data for BI-456906, a novel long-acting glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, currently in phase II development in patients with obesity and nonalcoholic steatohepatitis (NASH).
Researchers from Roche Holding AG disclosed the discovery and preclinical evaluation data for RG-7774 (vicasinabin), a novel cannabinoid CB2 receptor (CB2R) agonist being developed for the treatment of diabetic retinopathy (DR).
Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise.
RSS
